CAJ | 학술논문

目的观察人工肝技术和肝移植手术对重症乙肝患者乙肝病毒标志物的影响.方法乙肝三系统定量采用时间分辨免疫荧光技术,乙肝病毒DNA定量采用实时荧光定量PCR法.结果 28例实施人工肝技术的重型肝炎患者治疗前后的乙肝三系统定量和HBV DNA定量结果为:HBsAg171.19±32.10 ng/mL,HBeAg 0.03±0.029 NCU/mL,抗-HBe 3.97±4.61 NCU/mL,抗-HBc 5.98±3.31 NCU/mL,HBV DNA(1.1×107)土(6.81×106)copy/mL和HBsAg 168.14±39.40 ng/mL,HBeAg 0.02±0.023 NCU/mL,抗-HBe 3.95±4.34 NCU/mL,抗-HBc 6.41±3.13 NCU/mL,HBVDNA(1.1 × 107)±(6.23×106)copy/mL,P值均大于0.05,差异无统计学意义.26例施行肝移植手术的患者治疗前后的乙肝三系统定量和HBV DNA定量结果分别为HBsAg 144.65±77.00ng/mL,HBeAg 0.02±0.028 NCU/mL,抗-HBe 4.32±6.43 NCU/mL,抗-HBc 6.04±4.88 NCU/mL,HBV DNA(1.0×107)±(6.89×105)copy/mL和HBsAg 6.54±3.32 ng/mL,HBeAg 0.02±0.016 NCU/mL,抗-HBe 4.79±6.44 NCU/mL,抗-HBc 5.97±4.64 NCU/mL,HBV DNA(1.04×103)±(3.40×102)copy/mL.除抗-HBe和抗-HBc,P值大于0.05外,其他项目P值均小于0.05,差异有统计学意义.结论肝移植手术可有效清除乙肝患者体内的乙肝病毒,人工肝支持系统虽不能有效清除乙肝患者体内的乙肝病毒,但可改善重型肝炎患者体内严重紊乱的内环境,为肝移植手术创造合适的条件和机会,赢得宝贵时间.
목적 관찰인공간기술화간이식수술대중증을간환자을간병독표지물적영향.방법 을간삼계통정량채용시간분변면역형광기술,을간병독DNA정량채용실시형광정량PCR법.결과 28례실시인공간기술적중형간염환자치료전후적을간삼계통정량화HBV DNA정량결과 위:HBsAg171.19±32.10 ng/mL,HBeAg 0.03±0.029 NCU/mL,항-HBe 3.97±4.61 NCU/mL,항-HBc 5.98±3.31 NCU/mL,HBV DNA(1.1×107)토(6.81×106)copy/mL화HBsAg 168.14±39.40 ng/mL,HBeAg 0.02±0.023 NCU/mL,항-HBe 3.95±4.34 NCU/mL,항-HBc 6.41±3.13 NCU/mL,HBVDNA(1.1 × 107)±(6.23×106)copy/mL,P치균대우0.05,차이무통계학의의.26례시행간이식수술적환자치료전후적을간삼계통정량화HBV DNA정량결과 분별위HBsAg 144.65±77.00ng/mL,HBeAg 0.02±0.028 NCU/mL,항-HBe 4.32±6.43 NCU/mL,항-HBc 6.04±4.88 NCU/mL,HBV DNA(1.0×107)±(6.89×105)copy/mL화HBsAg 6.54±3.32 ng/mL,HBeAg 0.02±0.016 NCU/mL,항-HBe 4.79±6.44 NCU/mL,항-HBc 5.97±4.64 NCU/mL,HBV DNA(1.04×103)±(3.40×102)copy/mL.제항-HBe화항-HBc,P치대우0.05외,기타항목P치균소우0.05,차이유통계학의의.결론 간이식수술가유효청제을간환자체내적을간병독,인공간지지계통수불능유효청제을간환자체내적을간병독,단가개선중형간염환자체내엄중문란적내배경,위간이식수술창조합괄적조건화궤회,영득보귀시간.
Objective To observe the effect of artificial liver technique and liver transplantation operation on hepatitis B markers (HBV M) of patients with severe chronic hepatitis B (SCH). Methods Time-resolved quantitative immunofluorescence technology was applied to quantitatively measuring hepatitis B markers,and real-time fluorescent PCR was adopted to quantitatively detect HBV DNA. Results The test results of HBV M and HBV DNA quantitation after and before artificial liver treat-ment in 28 cases of SCH were as follows: HBsAg (ng/mL) 168. 14 ± 39. 40 vs 171. 19 ± 32. 10; HBeAg (NCU/mL) 0.020±0. 023 vs 0. 030±0. 029; anti-HBe (NCU/mL) 3.95±4.34 vs 3.97± 4.61; anti-HBc (NCU/mL) 6.41±3.13 vs 5.98±3.31; HBV DNA (copy/mL) 1.1 × 107 ±6. 23 × 106 vs 1.1 × 107 ±6.81 × 106. There were no significant differences in HBV M and HBV DNA between after and before artificial liver treatment groups (P>0. 05). The test results of HBV M and HBV DNA quantitation after and before liver transplant operation in 26 cases of SCH were as follows: HB-sAg (ng/mL) 6.54±3. 321 vs 144. 65±77.00; HBeAg (NCU/mL) 0. 020±0. 016 vs 0. 020±0. 028; anti-HBe (NCU/mL) 4.79±6.44 vs 4.32±6.43;anti-HBc (NCU/mL) 5.97±4.64 vs 6.04±4.88; HBV DNA (copy/mL) 1.04 × 102 ± 3. 40 × 102 vs 1.0 × 107 ± 6. 89 × 106. There were significant differences in HBsAg, HBeAg and HBV DNA between after and before liver transplant operation groups (P<0.05). Conclusion Liver transplant operation effectively eliminates HBV in vivo. Artifi-cial liver treatment can not eliminate HBV in patients, but it may ameliorate the disordered internal en-vironment of SCH patients,and provide the patients an opportunity of liver transplant operation.